ARK Investment Management sold its position in Twist Bioscience as part of a $64.2 million divestment across three companies, including Iridium Communications and Robinhood Markets. The selloff, totaling $222.9 million across 20 stocks, occurred ahead of SpaceX’s $1.77 trillion IPO debut.
ARK Investment Management sold its stake in Twist Bioscience as part of a larger $64.2 million divestment from three companies, including Iridium Communications and Robinhood Markets. This transaction contributed to a total of $222.87 million sold across 20 stocks on June 11.
The sale occurred on the eve of SpaceX’s IPO, which was priced at $135 per share and valued at $1.77 trillion. The timing has spurred speculation that ARK may reallocate capital toward the high-profile space venture following its market debut.
This divestment could exert short-term downward pressure on Twist Bioscience’s share price and prompt investors to reevaluate institutional demand for its DNA synthesis and genomic sequencing platform.
